The Plan
Forever does not have to mean forever. The regulatory tools exist. The medical science is advancing. The legal accountability is moving through courts. What the plan needs now is political will that doesn't reverse course when industry pushes back.
Updated federal momentum
Congressional bill H.R. 3639 β the VET PFAS Act β adds bipartisan weight to the Plan by recognizing PFAS harms for veterans, dependents, and family members at contaminated installations.
β The Plan Is Under Active Attack
In April 2024, the EPAEPA β Environmental Protection AgencyThe U.S. Environmental Protection Agency (EPA) is the federal agency responsible for protecting human health and the environment by regulating pollutants β including the drinking-wβ¦ finalized the first enforceable maximum contaminant levels for PFAS in drinking water β 4 ppt for PFOA and PFOS, 10 ppt each for PFNA, PFHxS, HFPO-DA (GenX), and PFBS. That standard is now being dismantled.
On May 18, 2026, the EPA proposed to rescind the limits for four of the six regulated compounds β PFHxS, PFNA, GenX (HFPO-DA), and PFBS β while retaining the PFOA and PFOS limits but extending the compliance deadline to 2031. This is not a delay. It is a reversal of the only enforceable federal protections against documented exposure pathways for neurodevelopmental harm, infant mortality, and cancer.
A federal court blocked the rescission in January 2026. The fight is still active. The proposed rules are still on the docket. Your comment becomes part of the federal record.
Virtual Public Hearing
July 7
2026
The EPA's virtual public hearing on the proposed PFAS rollback has concluded. Oral testimony went directly into the docket β often weighted more heavily than written comments alone.
β Testimony delivered & entered into Docket EPA-HQ-OW-2025-0654 β see the recording below.
On the Federal Record Β· July 7, 2026
I Delivered This to the EPA
Oral testimony at the EPA's virtual public hearing on the Compliance Extension Rule β Docket EPA-HQ-OW-2025-0654. It went into the docket at the buzzer. This is the comment, exactly as delivered:
The comment, as delivered β full transcript
My name is Michael Kissling. I run AbilityForge.net.
The United States spends more per capita on healthcare than any other developed nation. Most of those nations have universal coverage. And most of them are actively moving to remediate PFAS from their water supplies—because they did the math. Cleanup is cheaper than chronic disease.
Make no mistake these chemicals, are a pathogen and a threat to human life. With a 191% increase in infant first year deaths. No speculation—counted tiny coffins per 1000 births that already happened. Longer waits to start cleanup is more tiny coffins per day.
Peer-reviewed research links PFAS exposure to Chronic conditions. Endocrine disruption. Developmental Delays. Cancers.
There is a Bipartisan Vet PFAS act in the 119th congress. Not just veterans… civilians… wives… children… because the exposure is carried for years. The mother’s levels go down… as the baby nurses. And you macrodose a microhuman.
A PFAS blood panel costs $300 to $400. A documented treatment protocol achieved a 60% average reduction in PFOS blood levels in study participants. For the cost of treating one PFOS-related cancer patient—you could screen and begin treating approximately 500 people.
Willow Grove was tested in 1996 and 2002. Neither tested for PFOS—not because they were careless, but because 3M and DuPont suppressed the science that would have told them what to look for. Their defrauding of the US Government has caused the military to lose face for too long.
Food safe filters with pasteurized Egg whites presents a possible extremely cheap filtration method. Invented by North Dakota State University.
Verbatim, as entered into the docket July 7, 2026. The recording above is the same comment as spoken.
What You Can Do β What We Did
What AbilityForge Did
Formal EPA Public Comment β Submitted & Tracked
On June 15, 2026, AbilityForge submitted a formal eight-section public comment to Docket EPA-HQ-OW-2025-0654, opposing the proposed rescission of MCLs for PFHxS, PFNA, HFPO-DA, and PFBS. A tracking number was issued β the comment is now part of the permanent federal administrative record.
The Comment Covers:
What You Can Do β Now
Three Actions Β· One Deadline
Action 1 Β· Concluded July 7
Virtual Public Hearing β Testimony Delivered
The hearing has concluded. AbilityForge testified on July 7 β the oral comment is on the docket.
Watch the delivered testimony βAction 2 Β· Deadline July 20
Submit Your Own Public Comment
Your comment β even one paragraph β becomes part of the permanent federal record. Personal stories from veterans, families, and anyone near a contaminated site carry real evidentiary weight for future litigation.
Submit Comment β regulations.govAction 3 Β· No Deadline
Contact Your Representative β Support H.R. 3639
The VET PFAS Act (H.R. 3639) needs co-sponsors. Ask your representative to sign on. If you are a veteran or family member of a veteran who served at a contaminated installation, say so.
View H.R. 3639 on Congress.gov βTable of Contents
- The Plan Is Under Active Attack
- What You Can Do β What We Did
- The Regulatory Framework
- Medical Countermeasures
- The $340 Proposal: The Case for Prevention
- For Clinicians: PFAS Exposure Provider Guide
- Bio-Remediation: Nature's Filter
- Legal Accountability
- The Legislative Path
- Case Study: Charles DeSautel
- The Infestation & Final Truth
- Closing Statement
The Regulatory Framework
EPA 2024 PFAS Rule
The 2024 EPA National Primary Drinking Water Regulation established enforceable maximum contaminant levels for six PFAS compounds β the first such limits in U.S. history. Key limits:
Compare: Willow Grove on-base wells β 13,700 ppt PFOS.
The Class-Based Argument
A major scientific review argues that regulating PFAS compound-by-compound is a failed strategy. With over 12,000 variants, manufacturers can simply switch to slightly modified alternatives and repeat the cycle.
Scientists are calling for class-based regulation β treating all PFAS as a single category β to close the substitution loophole that has allowed the industry to evade accountability for decades.
Read the Case for Class-Based Regulation βMedical Countermeasures
Cholestyramine: The First Controlled Clinical Trial
The first randomized controlled clinical trial of cholestyramine for PFAS body burden reduction was published in Environment International (MΓΈller et al., 2024, University Hospital of Holbaek / University of Copenhagen). Cholestyramine is an anion exchange resin β an FDA-approved drug with decades of safety data, originally developed for cholesterol reduction. The mechanism: it interrupts the enterohepatic recirculation of PFAS in the gut, preventing reabsorption and increasing fecal elimination.
60%
Decrease in serum PFOS over 12 weeks (p < 0.0001)
12 wks
Treatment duration Β· 4g three times daily
15β44%
Additional PFAS reduced: PFHxS, PFOA, PFNA, PFDA
0
Serious adverse events reported across 45 participants
This is not experimental. Cholestyramine is an existing, approved, generic medication available at pharmacies. The RCT establishes its use for PFAS biosequestration as a documented, evidence-based clinical intervention.
Water Filtration: Anion Exchange Resin
The same chemical mechanism that makes Cholestyramine effective for body burden reduction also works at the water treatment level. Studies confirm that anion exchange resin treatment produces substantial decreases in PFAS levels in drinking water β offering both a source-control and a body-burden-reduction approach from the same class of technology.
German researchers have also developed nanoscale "covalent organic frameworks" β filter materials with pores just nanometers across that trap PFAS molecules. The material is produced using an environmentally sustainable ball-mill technique, offering a path toward industrial-scale filtration.
The $340 Proposal: The Case for Prevention
A Documented Cost-Effectiveness Argument
The answer to "what's causing the rise in chronic disease and neurodevelopmental disorders" may already be in the peer-reviewed literature. If so, there is a documented, inexpensive, FDA-approved intervention available right now.
What the Research Documents
- 1.PFAS is present in the blood of the vast majority of Americans. It crosses the placenta, appears in breastmilk, and accumulates in the body over decades β with half-lives of 3β8 years per compound.
- 2.PFAS is associated with prostate cancer, colorectal cancer, thyroid disease, endometrial cancer, kidney cancer, immune dysfunction, and β per two peer-reviewed literature reviews from 2024β2025 β ASD and ADHD via disruption of dopamine signaling.
- 3.A randomized controlled trial (MΓΈller et al., 2024) demonstrated that cholestyramine β a generic, FDA-approved drug already on pharmacy shelves β reduces serum PFOS by 60% in 12 weeks, with no serious adverse events.
- 4.PFAS blood testing is available now, direct-to-consumer, through Quest Diagnostics using the NASEM 7-analyte panel. No physician referral required in most states.
What It Would Cost
NASEM 7-analyte panel Β· Quest Diagnostics Β· Identifies exposure tier and compounds present
FDA-approved Β· Available at most pharmacies Β· GoodRx pricing in many cases significantly lower
The Prevention Math
$340
Screen + treat
one exposed person
vs.
For the cost of treating
one cancer patient
500+
People screened
and treated
Average cancer treatment cost in the United States exceeds $150,000. At $340 per person, that same expenditure screens and treats more than 440 exposed individuals β removing the body burden before it progresses to cancer, diabetes, thyroid disease, or neurodevelopmental harm in the next generation.
A Matter of Public Record
The stated goal of identifying the cause of rising autism prevalence was announced publicly, with a target date of November 2025. It is now June 2026. Two major peer-reviewed literature reviews β from researchers at Kaiser Permanente, Drexel University's Autism Institute, the University of Georgia, and the federal NIEHS / National Toxicology Program β document PFAS as associated with ASD and ADHD, with a plausible neurological mechanism involving disruption of dopamine signaling. These papers were published in 2024 and 2025, while the target date passed.
The answer may not have been the one that was expected. But it is the one the evidence is pointing at. And unlike most public health challenges, this one has a cheap, existing, safe, FDA-approved intervention ready to deploy today β for less than what most Americans spend on a car payment.
The proposal: screen every American from a documented PFAS-contamination community. Treat those above the clinical threshold. Measure the outcomes. The cost per person is lower than most lab panels. The potential return β in cancer prevention, reduced diabetes burden, and neurodevelopmental protection for the next generation β is not speculative. The endpoints are documented on both sides.
For Clinicians: PFAS Exposure Provider Guide
PFAS Exposure: Clinical Summary for Providers
A concise clinician reference for physicians and practitioners managing patients with potential PFAS exposure. Covers risk stratification, diagnostic protocol, remediation thresholds, and evidence-frontier findings not yet reflected in EPA/ATSDR guidance.
- β NASEM 7-analyte summation panel protocol (Quest Diagnostics)
- β Three-tier clinical action framework (<2 / 2β20 / β₯20 ng/mL)
- β Cholestyramine sequestrant threshold and mechanism
- β Enterohepatic loop disruption β the accessible intervention point
- β Evidence frontier: HMGCS2 downregulation, NF-ΞΊB invasion pathway
- β Veterans Note: VA service-connection precedent for Willow Grove NAS
AbilityForge Clinical Resource Β· v1.4
NASEM 2022 aligned Β· For clinicians and patients
Bio-Remediation: Nature's Filter
The same chemistry that makes PFAS persistent β its affinity for protein hydrophobic binding sites β is also the key to its removal. Naturally occurring proteins bind PFAS at the molecular level. This is not speculative. It is being confirmed in peer-reviewed research at the water source, in the gut, and in the bloodstream simultaneously.
Ovalbumin β Egg White Protein
Research published in Cell Reports Physical Science (2026) by teams at NDSU and Iowa State confirmed that ovalbumin β the primary protein in egg whites β binds PFOA and PFOS spontaneously at the atomic level. The arginine and lysine residues in ovalbumin act as molecular hooks, wrapping around and trapping PFAS molecules with high affinity.
- β Binds 7+ PFAS types including PFOA and PFOS
- β More efficient than activated carbon filtration
- β Deployable as gels or sheets for municipal water treatment
- β Bio-based, scalable, sustainable production pathway
The same protein-binding chemistry that makes PFAS persistent in the body is the mechanism used to extract it from water.
Okra β Natural Mucilage Filtration
Okra's natural mucilage β the viscous polysaccharide that makes it distinctive in cooking β has been identified as an effective, low-cost PFAS-binding agent for water filtration. The mucilage acts as a natural flocculant, capturing PFAS and other contaminants and allowing them to be separated from the water supply.
- β Abundant, inexpensive, globally available crop
- β Biodegradable β no secondary contamination from the filter itself
- β Applicable at household, community, and municipal scale
- β Represents an accessible remediation pathway for under-resourced communities near contamination sites
The communities most likely to be contaminated are often the least resourced to address it. Okra changes that equation.
The Binding Chain principle: The same hydrophobic protein-binding chemistry captures PFAS in water, in bile, and in blood. Remediation is possible at all three scales β water source, gut lumen, and blood serum. These are not three separate problems. They are one mechanism at three scales.
Legal Accountability: The Settlements Are Moving
$2B
New Jersey secured from DuPont, Chemours, and Corteva β largest environmental settlement in state history. Funds remediation at four major industrial sites.
$4.9M
Paid to 60,000 New Jersey water customers from 3M and Middlesex Water Co. This case may become a template for communities nationwide.
$4M
Columbus, Ohio received initial settlement from 3M and others. City Attorney: "These companies β not ratepayers β are on the hook for cleaning up their mess."
The VA Gap
While civil courts move forward, the VA still offers no presumptive service connection for PFAS-related cancers. Veterans are required to individually prove their cancer was caused by their service exposure β placing the full burden of proof on sick servicemembers while the VA states it is "reviewing scientific evidence."
Civil lawsuits are now defining the specific damage list that regulators are too slow to acknowledge. The legal record is building the case that the VA is not yet required to accept.
The Legislative Path
State-Level Movement
As of 2025, at least 14 states have passed legislation establishing PFAS remediation funds, phasing out AFFF use, or setting enforceable drinking water limits. Massachusetts, New Jersey, and others are models for state-level action that does not wait for federal movement.
The AFFF Ban
A ban on PFAS-containing AFFF has been legislated β but faces active efforts to delay implementation. The foam used at 630 military bases has been confirmed to contaminate drinking water or groundwater. Delaying the ban extends that contamination footprint in real time.
Cleanup Funding
The DOD has delayed PFAS cleanup at more than 100 military bases. Cleanup funding has been the subject of congressional battles β with documented efforts to cut remediation budgets alongside the contamination evidence. The cleanup roadmap exists. The appropriations remain contested.
VET PFAS Act: Bipartisan Momentum
House Bill H.R. 3639, the "Veterans Exposed to Toxic PFAS Act" or "VET PFAS Act," was introduced May 29, 2025. It has bipartisan sponsors from both sides of the aisle, and it explicitly expands the federal response to include veterans, dependents, and family members exposed at PFAS-contaminated military installations.
Key provisions in the bill include:
- Hospital care and medical services for veterans exposed to PFOA and other PFAS at covered military installations, even when direct causation is not fully documented.
- A new VA care authority for family members and dependents who lived at the same contaminated installations or were exposed in utero.
- A presumption of service connection for certain PFAS-related diseases and conditions, including high cholesterol, ulcerative colitis, thyroid disease, testicular cancer, kidney cancer, and pregnancy-induced hypertension.
- A federal standard for treating reserve-component service at contaminated sites as active-duty service for these benefits.
Case Study: Charles DeSautel
Published With Patient Permission
Willow Grove NAS β A Veteran's Documented Exposure
Charles DeSautel served at Willow Grove Naval Air Station β a confirmed PFAS contamination site where AFFF firefighting foam was used extensively. His PFAS blood panel, drawn December 2025, returned a NASEM summation of 9.06 ng/mL β placing him in the enhanced screening tier. But that number tells only part of the story.
PSA Trajectory β The Timeline of Institutional Failure
Normal range: <4.0 ng/mL Β· Gleason 4+3 Β· Grade Group 3 Β· 5/35 cores positive Β· VA record
β D'Amico >2.0 ng/mL/yr = significantly shorter time to deathDeaththe act of dying; the end of life; the total and permanent cessation of all the vital functions of an organism. (D'Amico et al., NEJM)
Biopsy Result
Gleason 4+3
Grade Group 3 Β· 5/35 cores positive Β· Perineural invasion present Β· Right posterior medial dominant (75% core involvement)
PFAS Panel (Dec 2025)
9.06 ng/mL
NASEM summation Β· PFHxS 5.40 ng/mL (7β8 yr half-life) Β· Linear PFOS: assay interference β unmeasurable Β· Peak burden estimated 4β10Γ higher at exposure
Current Status
PET CT: Apr 24
NM PET CT Skull Base to Mid Thigh Β· Cholestyramine active Β· Treatment decision pending staging Β· VA service connection claim in process
The Lagging Indicator Problem β In One Person's Blood
Chuck's exposure at Willow Grove NAS occurred approximately 16 years before his blood was tested. PFHxS carries a 7β8 year serum half-life. At 16 years post-exposure, his current 5.40 ng/mL PFHxS back-calculates to an estimated 21β27 ng/mL at peak β for that single analyte alone. Linear PFOS, the compound most strongly associated with military AFFF and the primary Willow Grove contaminant, could not be measured due to assay interference from his active cholestyramine treatment.
His NASEM summation of 9.06 ng/mL today β more than a decade of decay into his cancer diagnosis β almost certainly represents a peak burden that cleared the β₯20 ng/mL expanded cancer surveillance threshold years before any clinician looked. The damage preceded the diagnosis. The diagnosis preceded the action. The action is now a race.
"I want people to know what was found. People can get blood testing. People can get treatment to remove the chemical. Hopefully that reduces cancer clusters. We need to clean it up as well so more people don't get sick."
β Charles DeSautel, Willow Grove NAS Veteran Β· Published with permission
Are you a Willow Grove NAS veteran or family member? PFAS serum testing is available direct-to-consumer through Quest Diagnostics (NASEM 7-analyte panel). Cholestyramine, an existing approved medication, has been shown in a landmark randomized controlled trial to reduce PFOS serum levels by 60% in 12 weeks. The VA has recognized PFAS contamination at Willow Grove NAS as a qualifying exposure basis. You do not have to wait for the system to act first.
The Infestation & Final Truth
The Infestation & Final Truth
AbilityForge Β· Michael Kissling Β· 2026
Powerful cinematic hard rock Β· 95 BPM
Willow Grove NAS Β· Charles DeSautel Β· PACT Act